Overview

• US drug delivery device maker's preliminary Q2 revenue rose 21% yr/yr to $2.8 mln

• Medical segment revenue expected to rise 300% yr/yr in Q2, driven by international orders and base business expansion

Outlook

• Company expects medical segment momentum to accelerate in Q3 2026

• Milestone Scientific anticipates more meaningful revenue contributions later in 2026

• Company plans to secure dental registrations in Japan, Mexico, Turkey, and India in coming quarters

Result Drivers

• BASE BUSINESS EXPANSION - Co said core business performed well, contributing about $2.4 mln in Q2 revenue

• INTERNATIONAL ORDERS - About $500,000 in Q2 revenue attributed to international orders, reflecting global demand for technology

• MEDICAL SEGMENT GROWTH - Medical segment revenue expected to rise 300% yr/yr in Q2, with progress on reimbursement claims

Company press release: ID:nGNXbWk5T3

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Preliminary Q2 Revenue	Beat	$2.80 mln	$2.50 mln (2 Analysts)

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Milestone Scientific Inc is $1.00, about 211.5% above its June 30 closing price of $0.32

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.